

**Ω**  
**OMEGA**  
OFFICIAL TIMEKEEPER



# THE TIMES OF INDIA

\* INCLUSIVE OF AHMEDABAD TIMES (FOR AHMEDABAD AND GANDHINAGAR CITIES ONLY)



**BUSH WANTED TO GET ME KILLED, SAYS VENEZUELAN PREZ HUGO CHAVEZ 17**

**RELIANCE Mobile**

GSM service  
Call 1833 or 3023 3333

**Grab the Gr8 numbers**

First time in Gujarat '0000' series of Mobile numbers.

**FLINTOFF DIDN'T WANT TO PLAY TEST SERIES AFTER 26/11 ATTACKS 21**



## NEWS DIGEST

### Indian taxi driver attacked by Oz footballer

In yet another attack on an Indian in Melbourne, a taxi driver from the community was injured when a drunk Australian star footballer allegedly assaulted him after an altercation. Essendon football player Michael Hurley was arrested for kicking and punching an Indian cabbie outside a fast-food outlet on Hoddle Street. **P 17**

### Hospitalise Shiney Ahuja, says court

A sessions court on Friday directed the Arthur Road prison authorities to administer medical treatment to actor Shiney Ahuja, arrested for allegedly raping his maid, and shift him to a hospital if required, after he complained of acute back pain. **P 15**

### Kirsten denies sex advice

India's cricket coach Gary Kirsten on Friday expressed his deep hurt and anguish at the quotes attributed to him that he has been trying to encourage the players towards sexual activity in order to improve their performance. **P 21**

### DIWALI KI MITHAAS

Vishy wishes to spread more joy: Chess grandmaster Vishwanathan Anand loves Diwali and the energy it generates. Personally, he makes it a point to burst crackers with family, share sweets and help the underprivileged. He rues the fact that as a sportsman, he has to constantly travel and miss such moments of happiness. **Look inside for more**

**DAIRY MILK**  
**ISS DIWALI AAP KISI KHUSHI KARENGE?**

**Rs 5,000-cr hawala scam busted:** An Indian businessman with alleged links to Dawood Ibrahim and Al Qaida and accused of terror financing by US Homeland Security was on Friday booked by enforcement directorate for running an alleged hawala operation to the tune of Rs 5,000 crore. **P 12**

## Gujarat cows take on H1N1, HIV

### Amul Launches Oral Spray To Strengthen Immune System

Raja Bose | TNN

**Anand:** It will now be cow versus swine. As the world grapples with H1N1, cows in Anand, the country's milk capital, will provide the all-important ingredient to tackle the menace.

After giving the country utterly, butterly, delicious milk products for almost five decades, Amul is ready to take on deadly viruses as it joins hands with a Mumbai-based company to collect 'first milk' — which provides immunity to the new-born calf — to come out with an oral spray that increases the human's immune system against viruses, including HIV and H1N1.

The milk is being collected from Amul's milk cooperatives and the product, Receptor, will be

marketed by the Gujarat Cooperative Milk Marketing Federation (GCMMF) which owns the Amul brand.

"The first milk from the mother's breast, called colostrum, helps the offspring build its immune system. We first removed fat by nano filtration from the colostrum collected from cows. The isolated particles, called nano-peptides, were named 'Radha-108'. It has been patented in India and the US. If sprayed in the mouth, these nano-peptides reach the heart from where it is pumped around the body," says Dr Pawan Saharan, chairman of Biomix Network Limited, who got a soft loan of Rs 12 crore from the department of science and technology to conduct the research.

"This is a paradigm shift in re-



search as it aims at strengthening the body against the virus. These nano-peptides block pores (receptors) on the cell surface that are gateway to viruses and also height-

en the immune system in case of a viral attack," says Dr Saharan.

"Clinical trials have been conducted in the US, Nigeria and India. HIV patients have shown drastic reduction in viral load and those with influenza have turned asymptomatic," he adds.

While Biomix has applied to the Drugs Controller General of India, Receptor is being sold as a natural food supplement at eight counters at Mumbai's domestic and international airports.

"This is Amul's first foray into this field. Amul has provided land for research and production," says GCMMF chairman BM Vyas. The plant has come up at Amul Dairy premises in Khatraj near Ahmedabad. About 1,200 members of Amul's village cooperatives source colostrum from cows.

## Bill soon to protect you from fleecing builders

Mahendra Kumar Singh | TNN

**New Delhi:** The aam aadmi looking to own a piece of real estate might be able to breathe easier. The possibility of being hoodwinked by a smooth-talking builder or salesman might be reduced sharply as developers will soon be required to post project details, including civic clearances, on the website of the real estate regulator.

Being turned into a real life victim of sharp builders, featured in the film 'Khosla ka Ghosla', has given nightmares to honest property buyers often duped by developers hiding behind terms like 'super area' and fine print about various 'charges' to conceal actual floor area and the final costs.

### Providing A Solid Foundation



- ▶ Builders will have to register with regulator and provide details of number and size of plots, layout plan and other facilities before launching any project
- ▶ They will not be able to take any advance payment from buyer without written sale agreement mentioning project timeline, payment details and possession date
- ▶ Promoter can't cancel sale deed unilaterally. Will have to give notice and provide entire amount with interest
- ▶ Buyers will have to be clearly told the carpet area, super area, common area and other specifications of apartments by the promoter
- ▶ If developers fail to provide services like supply of electricity, water, sewage and drainage, consumers can approach the regulator for relief

## AI pilots threaten mass sick leave

Saurabh Sinha & Neha Lalchandani | TNN

**New Delhi:** Barely two weeks after a strike by Jet pilots plunged flight schedules into chaos, several vacation plans for the festive season could be hit following a threat by nearly one-third of Air India pilots to go on indefinite strike from Friday midnight by reporting sick en masse.

On Wednesday, cash-strapped AI had slashed salaries of non-unionised executive pilots belonging to the management cadre. The aggrieved pilots — 400 in all — have now hit back and are

## JuD man at helm, PTV shuns news against Taliban

Omer Farooq Khan | TNN

**Islamabad:** Pakistan's government-owned news channel, PTV, has officially been in the hands of a known activist of the banned Jamaat-ud-Dawa (JuD), Imran Meer, since March this year. Meer was a spokesperson of the JuD and familiar to the people as the man with the flowing beard and cropped hair, holding brief for the activities of the banned organisation.

While the Pakistani government constantly harps that it has no links to Hafiz Saeed and his jihadis, it thinks nothing of making a major jihadi sympathiser a part of the establishment by handing him the keys to the government-owned propaganda machinery — a role in which Meer has excelled by blacking out every bit of anti-Taliban and anti-Hafiz Saeed news.

Meer was hired on the recommendations of the information ministry investigations and interviews with members of the now-defunct JuD and media organisations reveal that Meer frequently voiced the views and statements of JuD leaders. "He has been seen at the Raiwind facility of the organization on a number of occasions," said an activist of the banned JuD.

Once entrenched in PTV, Meer got in another alleged JuD activist, Zafar Malik, as director production. Malik is

### Official Blackout

▶ Imran Meer was spokesman of JuD, edited outfit's mouthpiece and remains a prominent jihadi sympathizer

▶ Blacks out news against Taliban, Hafiz Saeed

▶ Hired on recommendations of the information ministry, Meer in turn brought in another alleged JuD man, Zafar Malik, to head production at PTV

▶ Malik linked to jihadi outfits in Kashmir and Afghanistan, was detained by FBI after Daniel Pearl's murder

the persons to vouch for Meer was Peshawar-based spokesperson of JuD, Atiq Chauhan, who told TOI that Meer was a deputy editor of the organization's newspaper, Ghazva. Apart from bringing out JuD's mouthpiece, Meer is not known to have had any journalistic experience.

Question is, how does the government distance itself from JuD when its only official news channel is controlled by JuD activists?

PTV News has also reported instances of sexual harassment of female anchors and at least three of them have filed complaints with the information ministry accusing director current affairs, Ahsan

growth, which is reflected in hiring across sectors. Besides IT, energy, power and infrastructure, which are hiring in a big way, even business process outsourcing (BPO)

Monster India BPO (South-East Asia and West Asia). However, besides the IT and financial sectors, where commitments are being made mostly at the entry levels, oth-

level management. Because there is a demand to fill up positions as companies look to expand slowly," says Shiv Agarwal, CEO, ABC Consultants.

At the top level, popularly known as the C-level, the hikes are even lesser. In some cases, aspirants are forego-

40 lakh, compared with Rs 43 lakh in 2007. Modi of Monster expects hiring in the IT sector to come back in cities like Bangalore.

(Additional reporting by Shivani Shinde from Mumbai and Kirtika Sunjja from New Delhi)

Published in Business Standard, Ahmedabad, DT 20/01/2010

# New vaccine may help cure multiple diseases

SOHINI DAS & MAULIK PATHAK  
Ahmedabad, 19 January

As the world's first dairy-based nano-biotechnology factory is readying for commercial production in Kheda district of Gujarat, there are very high hopes for the product, branded 'Receptol'.

It is described as likely to bring in a paradigm shift in the pharmaceutical world by helping cure most of the diseases we encounter today, barring some genetic disorders.

Funded by the Department of Science and Technology (DST), Mumbai-based Biomix Network has completed phase-III clinical trials of Receptol, a broad spectrum antiviral and immune modulator for the treatment of HIV, hepatitis and other viral and recurrent fungal and bacterial infections.

DST has agreed to fund one of the largest clinical trials of the country for tuberculosis (TB)

and multi-drug resistant (MDR) TB, involving 1,000 patients. Biomix is currently awaiting a nod from the Drug Controller General of India to conduct the trials.

"Receptol is a recipe for all, covering 90 percent of diseases that we encounter today. We plan to launch over 30 products over a period of five years, subject to necessary government approvals. These products will be specially designed by isolating the specific nano-peptides which are active in curing diseases like HIV/AIDS, hepatitis, tuberculosis, swine flu, bird flu, allergies, asthma, some forms of cancer, even neurological disorders like Parkinson's and Alzheimer's. This could be the next big thing after Penicillin," Pawan Saharan, chairman of Biomix Network told Business Standard.

The product was launched at Mumbai airport a few months earlier on a trial basis to check

swine flu, and Saharan plans to make it available at 160 airports across the world over three to four years.

The company has roped in Amul (the Gujarat Cooperative Milk Marketing Federation) for collecting bovine lacteal sources or the 'first milk' from cows af-

## Funded by the Department of Science and Technology, Mumbai-based Biomix Network has completed phase-III clinical trials of Receptol

ter a calf is born, and has managed to extract nano-peptides that act as active pharmaceutical ingredients (API). It has patented the compound in India as Radha-108.

The company has approval to market the product in South Africa and New Zealand, and had filed an application with the US regulator, the FDA, recently. When sprayed in the mouth, these nano-peptides reach the

heart, from where it is pumped around the body and eventually block pores on the cell surface that are a gateway to viruses and also heighten the immune system in case of a viral attack, is the explanation.

Bimix's plant has a capacity to manufacture two million

doses per month of Receptol spray, based on Radha-108. It has been set up at the premises of Amul's cheese manufacturing facility at Khakhraj for an investment of Rs 50 crore in the first phase. The company plans to raise \$25 million (Rs 115 crore). It would use the funds for expansion of the facility at Khakhraj and for a facility in the US as well.

"We have already tied up

with a multinational pharmaceutical company in the US to set up a manufacturing facility," Saharan claimed, without giving details.

The phase-I trials for Receptol happened in the US in 2004 at the Ohio State University, phase-II in the same year at Nairobi, while phase-III trials were conducted in Rwanda in Africa. "The results were presented before the Government of India on December 1, 2004, after which the Ministry of Health conducted revalidation trials under the aegis of the Indian Council for Medical Research (ICMR) in October 2005," Saharan informed.

The National Aids Control Organisation's apex research committee approval and funding for Phase-III Receptol Trial happened in December 2005. A Phase-III study for Receptol was conducted on 50 HIV seropositive patients at Lokmanya Tilak Municipal Medical College, Mumbai, in 2006.

The DST funded Rs 12.18 crore for the trials and has agreed to provide funding worth Rs 24 crore for the TB trials over 1,000 patients.

The company now plans to launch different formulations for Receptol by tying up with domestic pharmaceutical companies. While talks are on, Saharan did not want to give out details. He, however, added that a region-wise launch of Receptol is in the offing in two to three months and that the product would be available through Amul outlets across the country. The company has an understanding with Amul for sourcing of raw material and is working on a revenue-sharing contract as well.

"We plan to touch a turnover of Rs 100 crore by next (financial) year and the global turnover should touch \$100 million over the next three years," Saharan said. The pricing for a 96 ml bottle of Receptol would be around Rs 250.

# 'We will start a third shift at Halol for LCV'

General Motors India plans to start a third shift at the Halol plant near Ahmedabad to cater to the additional production requirement after the launch of a light commercial vehicle (LCV) in 2011. In a chat with Sohini Das, GM India President and Managing Director KARL SLYM says, with the launch of the new compact car Beat and a positive response to the Cruze, GM plans to cross the 100,000-unit mark this year in sales. The company has a slew of launches planned for this year, including the electric Spark, an upgrade of

a third shift will be started. As for the investment, we plan to make some modifications at the plant. We will also invest in tooling and equipment. But we are yet to arrive at exact figures.

Do you plan to source components for the LCV from China?

Bangalore-based Reva for sharing the technology to produce the electric Spark.

With the launch of the Beat, what kind of overall volumes do you expect this year?

We are bullish about growing by 50 per cent in terms of volumes this year, chiefly on the back



entre)  
ny, in

aid it  
ital  
ng at  
ar, "Digital  
vill  
to sell  
magawa

ials  
Biotech  
n of HN-  
e. The  
ntroller  
CMD  
IS REPORTER

s net profit  
rter ended  
1,611.60  
red with  
financial  
PTI

former VP-  
hot picks  
rd (West In-  
nder), who  
lukesh Am-  
lia, and New  
wler Shane  
on by Shah  
kata Knight  
ns bid over  
permitted  
000. In this

## **RECEPTOL ORAL SPRAY: BRIEF SYNOPSIS**

RECEPTOL<sup>®</sup> Oral Spray is an invention by Biomix Network Ltd. Proline rich polypeptides (PRPs) including Radha108 sequences are isolated through nanotechnology filtration system from bovine colostrum and formulated in a liquid oral spray to easily administer through buccal mucosa for effective penetration and effect.

RECEPTOL<sup>®</sup> Oral Spray is an immuno-modulatory product. It acts through regulating thymus, which in turn, modulates the function of immunity cells of the body. It increases the level of Interleukins and Cytokines. It blocks receptors of the immunity cells and restricts the entry of virus. Hence, body's own immune system improves and avoids recurrent viral infections.

RECEPTOL<sup>®</sup> Oral Spray was assessed as safe and effective for use in human population through clinical trials of Phase I, Phase II and Phase III in India and abroad, in the treatment of HIV and other immune disorders.

RECEPTOL<sup>®</sup> Oral Spray is manufactured in a controlled environment by skilled and trained personnel. Final filtration of the product through biological 0.2 $\mu$  filters ensures safe and microbial free product. Product Quality is ensured through stage-wise manufacturing and Quality Assurance controls.

RECEPTOL<sup>®</sup> Oral Spray containing Proline rich Polypeptides (PRPs) including Radha108 sequences shows that it is a new generation therapeutic agent, which is a highly effective, safe product for treatment of HIV and other immune disorders.

RECEPTOL<sup>®</sup> Oral Spray holds U.S. patent and South African patent.

## **BACKGROUND:**

Colostrum is a pre milk substance produced from mother's breast of all mammals during first 24hrs of lactation typically first 3 milks. Colostrum has been known as immune booster since time memorial. Colostrum triggers at least 50 processes in the newborn, including transferring all immune factors and the entire immunological memory from mother's own immune system. Bovine colostrum is up to 40 times higher than human colostrum in immune factors including nano-informational peptides, Proline rich polypeptides, immunoglobulins, cytokines, interferons, lactoferrin and transfer factors. They are produced by T-lymphocytes and can transfer the ability to recognize a pathogen to naive cells. However, no one till date has been able to isolate active ingredient especially nano informational low molecular weight nano peptides and formulate a product that has a same effect as that of mother's first 3 milks after birth of child.

## **INTRODUCTION:**

Biomix Network limited is successful in isolating active ingredients especially nano informational low molecular weight nano peptides that is Proline rich polypeptides(PRP) including Radha108 polypeptide sequences and provide a patient friendly liquid oral spray as immunomodulator.

## **TRIALS CONDUCTED**

**1) Pre clinical study (for acute and sub-chronic toxicity):** Carried out as per Appendix III, Schedule Y, at Nation Institute of Nutrition, Hyderabad (Acute Toxicity report in Module 2 of the dossier submitted).

**2) Phase I clinical trial:** Ohio, USA. The trial was conducted to evaluate safety of Receptol<sup>®</sup> Oral Spray on 12 HIV patients for period of 30days.

- No serious adverse effects were reported during the study.
- Improvement observed in HIV associated clinical symptoms.
- Weight gain was observed during the trial.

**3) Phase II study:** Nairobi, Kenya. Trial was conducted on 30 HIV patient for 90 days treatment of Receptol<sup>®</sup> Oral Spray with an objective to demonstrate, under clinical conditions efficacy and safety in patients known to have advanced disease (HIV/AIDS).

- Receptol<sup>®</sup> Oral Spray appeared to be safe and well tolerated.
- Significant value reduction in minimizing the infection associated with HIV/AIDS.
- Weight gain as a positive response.

**4) Phase III study:** Rwanda, Africa. Trial was conducted in 60 HIV patients for period of 12 months using Receptol<sup>®</sup> Oral Spray. The objective of study was similar to Phase II study.

- Receptol<sup>®</sup> Oral Spray appeared to be safe and well tolerated.
- Significant value reduction in minimizing the infection associated with HIV/AIDS.
- Weight gain as a positive response.
- Moderate level of relief from fever and diarrhea was observed.

**5) Phase III revalidation trial in India:** At Mumbai. 50 patients with HIV were treated with Receptol<sup>®</sup> Oral Spray for period of 12 weeks

- Primary efficacy results indicated reduction in HIV viral load and related clinical symptoms.
- Secondary efficacy results indicated increase in absolute CD4 cell counts and Gradual disappearance of clinical symptoms of fatigue/malaise, diarrhea, fever, cough, nausea, vomiting, disturbed sleep, skin rashes and Herpes Zoster.

All the above study in HIV/AIDS infected human concluded that Receptol<sup>®</sup> Oral Spray containing Proline rich polypeptides and Radha108 sequences indicated that it is new generation therapeutic agent which is highly effective against HIV and other immune disorders.

## **CONCLUSION**

Receptol<sup>®</sup> Oral Spray containing Proline rich polypeptide and Radha108 sequences show that it is a new generation therapeutic agent, which is highly effective and safe drug for treatment of HIV and other immune disorders.